Stockreport

Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing [Seeking Alpha]

Praxis Precision Medicines, Inc.  (PRAX) 
PDF Company believes that the essential tremor U.S. market opportunity could be $4 billion. Positive data achieved in phase 2 study, using PRAX-628 for focal epilepsy; Ph [Read more]